Paul George Jenkins
Vorstandsvorsitzender bei Cellesce Ltd.
Profil
Paul George Jenkins is currently the Chief Executive Officer and Director at Cellesce Ltd.
He previously worked as the Chief Executive Officer and Director at Adjuvantix Ltd.
and as the Vice President of Business Development at both Phoqus Pharmaceuticals Plc and West Pharmaceutical Services Group Ltd.
Jenkins holds a Master's in Business Administration from the London Business School.
Aktive Positionen von Paul George Jenkins
| Unternehmen | Position | Beginn |
|---|---|---|
Cellesce Ltd.
 Cellesce Ltd. BiotechnologyHealth Technology Cellesce Ltd. develops bioprocessing technology for organoids. Its products include colorectal cancer organoids and organoids of other human organs. The company was founded in 2013 and is headquartered in Cardiff, the United Kingdom. | Vorstandsvorsitzender | 01.08.2020 |
Ehemalige bekannte Positionen von Paul George Jenkins
| Unternehmen | Position | Ende |
|---|---|---|
Phoqus Pharmaceuticals Plc
 Phoqus Pharmaceuticals Plc Pharmaceuticals: MajorHealth Technology Phoqus Pharmaceuticals Plc develops pharmaceutical products. It's product Chronocort that helps to treat the patients with cortisol deficiency such as congenital adrenal hyperplasia and Addison's diseases. The company was founded in 1998 and is located in West Malling, UK. | Corporate Officer/Principal | - |
West Pharmaceutical Services Group Ltd.
 West Pharmaceutical Services Group Ltd. Financial ConglomeratesFinance Part of West Pharmaceutical Services, Inc., West Pharmaceutical Services Group Ltd. functions as an investment holding British company. The company is based in St. Austell, UK. | Corporate Officer/Principal | - |
Adjuvantix Ltd.
 Adjuvantix Ltd. BiotechnologyHealth Technology Adjuvantix Ltd. engages in the research and development of vaccines for the treatment of cancer and infectious diseases. Its initial vaccine development targets include prostate cancer, lymphoma and TB. The company's products include ADX40-TB, ADX40-prostate cancer and ADX40-lymphoma. Adjuvantix was founded by Andrew John William Heath on October 28, 1999 and is headquartered in Sheffield, the United Kingdom. | Vorstandsvorsitzender | - |
Ausbildung von Paul George Jenkins
| London Business School | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Adjuvantix Ltd.
Adjuvantix Ltd. BiotechnologyHealth Technology Adjuvantix Ltd. engages in the research and development of vaccines for the treatment of cancer and infectious diseases. Its initial vaccine development targets include prostate cancer, lymphoma and TB. The company's products include ADX40-TB, ADX40-prostate cancer and ADX40-lymphoma. Adjuvantix was founded by Andrew John William Heath on October 28, 1999 and is headquartered in Sheffield, the United Kingdom. | Health Technology |
Phoqus Pharmaceuticals Plc
Phoqus Pharmaceuticals Plc Pharmaceuticals: MajorHealth Technology Phoqus Pharmaceuticals Plc develops pharmaceutical products. It's product Chronocort that helps to treat the patients with cortisol deficiency such as congenital adrenal hyperplasia and Addison's diseases. The company was founded in 1998 and is located in West Malling, UK. | Health Technology |
West Pharmaceutical Services Group Ltd.
West Pharmaceutical Services Group Ltd. Financial ConglomeratesFinance Part of West Pharmaceutical Services, Inc., West Pharmaceutical Services Group Ltd. functions as an investment holding British company. The company is based in St. Austell, UK. | Finance |
Cellesce Ltd.
Cellesce Ltd. BiotechnologyHealth Technology Cellesce Ltd. develops bioprocessing technology for organoids. Its products include colorectal cancer organoids and organoids of other human organs. The company was founded in 2013 and is headquartered in Cardiff, the United Kingdom. | Health Technology |
